CRGT Cortigent, Inc.: ערך חשבונאי למניה

Cortigent, Inc. (CRGT) is currently deploying its accumulated capital toward costly research, as sales have not yet commenced. High venture capital expenditures and the complexities of implementing neuroprosthetics create significant risks. However, the unique Orion and Argus systems provide strong market power. Accounting data regarding the share price help assess net assets, where the mark characterizes this parameter.

Book value per share determines the portion of equity attributable to a single security after deducting all liabilities, serving as a fundamental indicator of the assets' intrinsic value. The current average book value per share stands at , reflecting the resilience of the asset base of Cortigent, Inc. (CRGT) amid geopolitical risks and potential disruptions in the supply of biopharmaceutical raw materials.